肿瘤穿透肽内化 RGD 通过减少肿瘤缺氧增强放射治疗效果。

Tumor-penetrating peptide internalizing RGD enhances radiotherapy efficacy through reducing tumor hypoxia.

机构信息

The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.

出版信息

Cancer Sci. 2022 Apr;113(4):1417-1427. doi: 10.1111/cas.15295. Epub 2022 Mar 11.

Abstract

Resistance to irradiation (IR) remains a major therapeutic challenge in tumor radiotherapy. The development of novel tumor-specific radiosensitizers is crucial for effective radiotherapy against solid tumors. Here, we revealed that remodeling tumor tissue penetration via tumor-penetrating peptide internalizing arginine-glycine-aspartic acid RGD (iRGD) enhanced irradiation efficacy. The growth of 4T1 and CT26 multicellular tumor spheroids (MCTS) and tumors was delayed significantly by the treatment with IR and iRGD. Mechanistically, iRGD reduced hypoxia in MCTS and tumors, resulting in enhanced apoptosis after MCTS and tumors were treated with IR and iRGD. This is the first report that shows enhanced radiation efficacy by remodeling tumor-specific tissue penetration with iRGD, implying the potential clinical application of peptides in future tumor therapy.

摘要

抵抗辐射(IR)仍然是肿瘤放射治疗中的主要治疗挑战。开发新型肿瘤特异性放射增敏剂对于有效治疗实体瘤至关重要。在这里,我们揭示了通过穿透肿瘤的肽内化精氨酸-甘氨酸-天冬氨酸 RGD(iRGD)重塑肿瘤组织穿透性可增强辐射疗效。用 IR 和 iRGD 处理可显著延迟 4T1 和 CT26 多细胞肿瘤球体(MCTS)和肿瘤的生长。在机制上,iRGD 减少了 MCTS 和肿瘤中的缺氧,从而在 MCTS 和肿瘤用 IR 和 iRGD 处理后增强了细胞凋亡。这是第一项表明通过用 iRGD 重塑肿瘤特异性组织穿透性来增强辐射疗效的报告,这暗示了肽在未来肿瘤治疗中的潜在临床应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ddc/8990783/9193c9427bc8/CAS-113-1417-g006.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索